BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
BRISTOL MYERS SQUIBB CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$58.83−0.92 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $120.48B
- P/E (TTM)
- 13.0
- Dividend yield
- 4.23%
Bristol Myers Squibb statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Market Cap | $120.17B | $197.05M |
| Enterprise Value | $152.23B | $106.56M |
| PE Ratio | 12.96 | 20.52 |
| PS Ratio | 2.44 | 3.93 |
| PB Ratio | 5.38 | 2.14 |
| P/FCF Ratio | 10.50 | 18.25 |
| P/OCF Ratio | 9.40 | 13.78 |
Enterprise value
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| EV / Sales | 3.09 | 2.69 |
| EV / EBITDA | 9.05 | 14.86 |
| EV / FCF | 13.31 | 21.02 |
Income (trailing twelve months)
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Revenue | $49.19B | $57.94M |
| Gross Profit | $34.51B | $90.47M |
| Pretax Income | $11.91B | -$14.45M |
| Net Income | $9.28B | -$22.46M |
| EBITDA | $16.82B | -$16.91M |
| EPS (Diluted) | $4.54 | -$0.83 |
Margins
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Gross Margin | 70.2% | 52.3% |
| Pretax Margin | 24.2% | -13.0% |
| Profit Margin | 18.9% | -39.2% |
| EBITDA Margin | 34.2% | -31.3% |
| FCF Margin | 23.3% | -8.85% |
Returns
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Return on Equity (ROE) | 46.7% | -53.1% |
| Return on Assets (ROA) | 10.2% | -41.0% |
Growth
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 3.11% | 6.01% |
| Net Income Growth (YoY) | 83.8% | -37.7% |
| EPS Growth (YoY) | 83.1% | -29.2% |
| FCF Growth (YoY) | -21.5% | 2.34% |
| Revenue Growth (3Y CAGR) | 1.45% | 2.25% |
| Revenue Growth (5Y CAGR) | 2.54% | 6.42% |
| EPS Growth (3Y CAGR) | 5.46% | -0.17% |
Balance sheet
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $11.07B | $62.42M |
| Total Debt | $43.12B | $120.13M |
| Net Cash (Debt) | -$32.05B | $15.68M |
| Net Cash Per Share | -$15.69 | $0.65 |
| Equity (Book Value) | $22.32B | $48.79M |
| Book Value Per Share | $10.93 | $1.36 |
| Tangible Book Value | -$16.81B | $23.06M |
| Working Capital | $9.92B | $75.77M |
Financial position
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Current Ratio | 1.53 | 3.30 |
| Quick Ratio | 1.08 | 2.39 |
| Debt / Equity | 1.93 | 0.51 |
| Debt / EBITDA | 2.56 | 3.35 |
| Debt / FCF | 3.77 | 5.05 |
| Net Debt / EBITDA | 1.91 | 2.22 |
Cash flow (trailing twelve months)
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Operating Cash Flow | $12.78B | -$12.35M |
| Capital Expenditures | -$1.34B | -$1.06M |
| Free Cash Flow | $11.44B | -$20.28M |
| FCF Per Share | $5.60 | -$0.41 |
Efficiency
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Asset Turnover | 0.54 | 0.38 |
| Inventory Turnover | 5.36 | 2.67 |
| Revenue Per Employee | $1.51M | $398.96K |
| Profits Per Employee | $285.60K | -$732.08K |
| Employee Count | 32,500 | 73 |
Dividends and yields
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Earnings Yield | 7.72% | -21.2% |
| FCF Yield | 9.52% | -7.64% |
| Dividend Yield | 4.23% | 1.83% |
| Shareholder Yield | 4.23% | 0.00% |
| Dividend Per Share | $2.49 | $0.83 |
| Dividend Growth (YoY) | 2.89% | 2.37% |
| Years of Dividend Growth | 11 | 0 |
| Payout Ratio | 54.9% | 47.7% |
| FCF Payout Ratio | 44.5% | 51.6% |
Shares
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Shares Outstanding | 2,042,710,000 | 59,128,900 |
| Shares Change (YoY) | 0.42% | 11.1% |
| Float | 2,041,600,000 | 48,744,500 |
| Shares Held by Insiders | 0.05% | 11.8% |
| Shares Held by Institutions | 81.9% | 59.4% |
Taxes
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Income Tax | $2.63B | $91.50K |
| Effective Tax Rate | 22.1% | 20.6% |
Scores
| Measure | Bristol Myers Squibb | Industry median |
|---|---|---|
| Graham Number | $33.41 | $17.36 |
| Graham Upside | -43.2% | -45.5% |
| Altman Z-Score | 2.13 | 0.10 |
| Piotroski F-Score | 8 | 4 |
| Beneish M-Score | -2.68 | -2.62 |
Calculated by StockData from Bristol Myers Squibb's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.